1.7299
price up icon3.59%   0.0599
after-market 시간 외 거래: 1.66 -0.0699 -4.04%
loading
전일 마감가:
$1.67
열려 있는:
$1.74
하루 거래량:
5,614
Relative Volume:
0.42
시가총액:
$12.59M
수익:
-
순이익/손실:
$-33.65M
주가수익비율:
-0.3887
EPS:
-4.45
순현금흐름:
$-20.83M
1주 성능:
-4.95%
1개월 성능:
+10.89%
6개월 성능:
-24.79%
1년 성능:
-43.83%
1일 변동 폭
Value
$1.68
$1.74
1주일 범위
Value
$1.566
$1.8812
52주 변동 폭
Value
$1.15
$3.499

미네르바 뉴로사이언스 Stock (NERV) Company Profile

Name
명칭
Minerva Neurosciences Inc
Name
전화
617-600-7373
Name
주소
1601 TRAPELO ROAD, WALTHAM, MA
Name
직원
8
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
NERV's Discussions on Twitter

NERV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NERV
Minerva Neurosciences Inc
1.7299 12.59M 0 -33.65M -20.83M -4.45
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-06-08 재확인 H.C. Wainwright Buy
2020-05-14 개시 BTIG Research Buy
2019-10-02 재확인 Chardan Capital Markets Buy
2019-09-25 개시 Chardan Capital Markets Buy
2019-09-18 개시 William Blair Outperform
2019-05-31 개시 H.C. Wainwright Buy
2017-09-01 개시 Citigroup Buy
2017-03-06 재개 Jefferies Buy
2016-05-12 재개 Jefferies Buy
모두보기

미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스

pulisher
Jun 12, 2025

Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Purchases New Holdings in Jiuzi Holdings, Inc. (NASDAQ:JZXN) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Citadel Advisors LLC - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Minerva Neurosciences Reports Q1 2025 Earnings and Regulatory Challenges - TipRanks

Jun 10, 2025
pulisher
Jun 04, 2025

Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
May 23, 2025

Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at Wall Street Zen - Defense World

May 23, 2025
pulisher
May 14, 2025

Minerva Neurosciences: Q1 Earnings Snapshot - CT Insider

May 14, 2025
pulisher
May 13, 2025

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

NERV's Cash Reserves Decrease by $4.1 Million in Q1 2025 | NERV Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Minerva Neurosciences Reports First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

MINERVA NEUROSCIENCES Earnings Results: $NERV Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Minerva Neurosciences, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World

May 13, 2025
pulisher
May 06, 2025

Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday - Defense World

May 06, 2025
pulisher
May 06, 2025

Renaissance Technologies LLC Has $285,000 Stock Holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World

May 06, 2025
pulisher
May 05, 2025

Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World

May 05, 2025
pulisher
May 01, 2025

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.

May 01, 2025
pulisher
May 01, 2025

Schizophrenia Market to Witness Significant Growth by 2034 - GlobeNewswire

May 01, 2025
pulisher
Apr 27, 2025

StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World

Apr 27, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 19, 2025

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World

Apr 19, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 13, 2025

StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - The AM Reporter

Apr 13, 2025
pulisher
Apr 10, 2025

CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 09, 2025

CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 04, 2025

Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Mar 24, 2025

Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com

Mar 24, 2025
pulisher
Mar 20, 2025

Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Minerva Neurosciences regains Nasdaq compliance - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire

Mar 19, 2025
pulisher
Mar 13, 2025

Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR

Mar 13, 2025
pulisher
Mar 07, 2025

Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech

Mar 07, 2025
pulisher
Mar 05, 2025

Minerva Neurosciences Reports Improved 2024 Financials - TipRanks

Mar 05, 2025
pulisher
Mar 02, 2025

Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World

Mar 02, 2025

미네르바 뉴로사이언스 (NERV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):